Advanced Search
- Cancer
- Chronic Diseases / Disorders
- Diabetes
- Diagnosis
- Fetal Alcohol Spectrum Disorder (FASD)
- Health Economics / Healthcare Costs
- Health Measurement Tools
- Health Policy
- Healthcare Services
- Infectious Diseases
- Maternal and Child Health
- Mental Health
- Other
- Pharmaceuticals
- Prevention
- Quality of Life
- Screening
- Surveillance
- Telehealth
- Therapy
- Brown, Jasmine
- Chojecki, Dagmara
- Corabian, Paula
- Escober-Doran, Carissa
- Guo, Bing
- Harstall, Christa
- Husereau, Don
- Institute of Health Economics, IHE
- Jacobs, Philip
- Jonsson, Egon
- Moga, Carmen
- Nguyen, Thanh
- Ohinmaa, Arto
- Scott, Ann
- Sproule, John
- Thompson, Angus
- Tjosvold, Lisa
- Waye, Arianna
- Yan, Charles
- Zheng, Yufei
Considerations on Subsequent Entry Biologics
PDF of a PowerPoint Presentation by Dr. Agnes Klein, Director, Centre for Evaluation of Radiopharmaceuticals and Biotherapeutics at Health Canada, Health Canada.
Biologic and Biosimilar Therapies: The Future of Biologic and Biosimilar Therapies for the Management of Rheumatoid Arthritis in Alberta Health Care Symposium
Note: Slide 16 of this presentation contains an error in the indications for Omnitrope. The correct indications can be found in the Product Monograph at the following link: Government of Canada - Omnitrope Product Information
Event Link: Biologic and Biosimilar Therapies
Year of Publication: 2014